These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38970127)

  • 21. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
    Yoshida K; Moein A; Bittner T; Ostrowitzki S; Lin H; Honigberg L; Jin JY; Quartino A
    Alzheimers Res Ther; 2020 Jan; 12(1):16. PubMed ID: 31969177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App
    Andersson E; Schultz N; Saito T; Saido TC; Blennow K; Gouras GK; Zetterberg H; Hansson O
    Alzheimers Res Ther; 2023 Mar; 15(1):64. PubMed ID: 36964585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
    Novak G; Streffer JR; Timmers M; Henley D; Brashear HR; Bogert J; Russu A; Janssens L; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
    Alzheimers Res Ther; 2020 May; 12(1):58. PubMed ID: 32410694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.
    Toda Y; Iwatsubo T; Nakamura Y; Matsuda N; Miyata M; Jin M; Chen T; Kuribayashi K; Tian Y; Hughes R; Yamamoto J; Muralidharan KK; Rubel C; Hutchison RM; Budd Haeberlein S
    J Prev Alzheimers Dis; 2024; 11(5):1260-1269. PubMed ID: 39350371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
    Turner RS; Hebron ML; Lawler A; Mundel EE; Yusuf N; Starr JN; Anjum M; Pagan F; Torres-Yaghi Y; Shi W; Mulki S; Ferrante D; Matar S; Liu X; Esposito G; Berkowitz F; Jiang X; Ahn J; Moussa C
    Ann Neurol; 2020 Jul; 88(1):183-194. PubMed ID: 32468646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.
    Galasko DR; Peskind E; Clark CM; Quinn JF; Ringman JM; Jicha GA; Cotman C; Cottrell B; Montine TJ; Thomas RG; Aisen P;
    Arch Neurol; 2012 Jul; 69(7):836-41. PubMed ID: 22431837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
    Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
    Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
    Craft S; Baker LD; Montine TJ; Minoshima S; Watson GS; Claxton A; Arbuckle M; Callaghan M; Tsai E; Plymate SR; Green PS; Leverenz J; Cross D; Gerton B
    Arch Neurol; 2012 Jan; 69(1):29-38. PubMed ID: 21911655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
    Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
    Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, tolerability and immunogenicity of an active anti-Aβ
    Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Pérez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleón I; San-José I; Munuera J; Rodríguez-Gómez O; Abdelnour C; Lafuente A; Buendía M; Boada M; Tárraga L; Ruiz A; Sarasa M
    Alzheimers Res Ther; 2018 Jan; 10(1):12. PubMed ID: 29378651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
    van Dyck CH; Mecca AP; O'Dell RS; Bartlett HH; Diepenbrock NG; Huang Y; Hamby ME; Grundman M; Catalano SM; Caggiano AO; Carson RE
    Alzheimers Res Ther; 2024 Jan; 16(1):20. PubMed ID: 38273408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.
    Galasko D; Bell J; Mancuso JY; Kupiec JW; Sabbagh MN; van Dyck C; Thomas RG; Aisen PS;
    Neurology; 2014 Apr; 82(17):1536-42. PubMed ID: 24696507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.
    Andreasen N; Simeoni M; Ostlund H; Lisjo PI; Fladby T; Loercher AE; Byrne GJ; Murray F; Scott-Stevens PT; Wallin A; Zhang YY; Bronge LH; Zetterberg H; Nordberg AK; Yeo AJ; Khan SA; Hilpert J; Mistry PC
    PLoS One; 2015; 10(3):e0098153. PubMed ID: 25789616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors.
    Van Broeck B; Timmers M; Ramael S; Bogert J; Shaw LM; Mercken M; Slemmon J; Van Nueten L; Engelborghs S; Streffer JR
    Alzheimers Res Ther; 2016 May; 8(1):21. PubMed ID: 27206648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
    Tsai RM; Miller Z; Koestler M; Rojas JC; Ljubenkov PA; Rosen HJ; Rabinovici GD; Fagan AM; Cobigo Y; Brown JA; Jung JI; Hare E; Geldmacher DS; Natelson-Love M; McKinley EC; Luong PN; Chuu EL; Powers R; Mumford P; Wolf A; Wang P; Shamloo M; Miller BL; Roberson ED; Boxer AL
    JAMA Neurol; 2020 Feb; 77(2):215-224. PubMed ID: 31710340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.
    Logovinsky V; Satlin A; Lai R; Swanson C; Kaplow J; Osswald G; Basun H; Lannfelt L
    Alzheimers Res Ther; 2016 Apr; 8(1):14. PubMed ID: 27048170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
    Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
    Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.